Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension

被引:146
作者
Silver, LH [1 ]
机构
[1] Alcon Labs Inc, Ft Worth, TX 76134 USA
关键词
D O I
10.1016/S0002-9394(98)00095-6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To determine the intraocular pressure-lowering efficacy and safety of brinzolamide 1.0%, compared with dorzolamide 2.0% and timolol 0.5%. METHODS: A multicenter, double-masked, prospective, parallel-group study was conducted to compare brinzolamide 1.0%, administered two and three times a day, dorzolamide 2.0% three times a day, and timolol 0.5% twice a day in 572 patients with primary open-angle glaucoma or ocular hypertension. The primary end point was diurnally corrected intraocular pressure reduction from baseline, evaluated at both peak and trough times during a 3-month period. RESULTS: Mean intraocular pressure changes after twice daily (-3.8 to -5.7 mm Hg) and three times daily (-4.2 to -5.6 mm Hg) dosing with brinzolamide 1.0% were statistically equivalent (confidence limit 11.5 mm Hg) to each other and also to dorzolamide 2.0% three times a day (-4.3 to -5.9 mm Hg). The range of intraocular pressure change with timolol 0.5% twice daily was -5.2 to -6.3 mm Hg. Clinically relevant intraocular pressure changes (reduction greater than or equal to 5 mm Hg or intraocular pressure less than or equal to 21 mm Hg) were observed in up to 75.7% of patients taking brinzolamide twice daily and in up to 80.1% taking brinzolamide three times daily. Treatment with brinzolamide 1.0% was safe, comfortable, and well tolerated. The incidence of ocular discomfort (burning and stinging) on instillation of brinzolamide (twice daily, 1.8%; three times daily, 3.0%) was significantly less (P = .000) compared with treatment with dorzolamide (16.4%). CONCLUSIONS: Brinzolamide 1.0% produced clinically relevant intraocular pressure reductions in substantial numbers of patients. Brinzolamide's effectiveness equaled that of dorzolamide 2.0% and it produced less ocular discomfort (burning and stinging) on instillation. (C) 1998 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:400 / 408
页数:9
相关论文
共 9 条
  • [1] Camras C. B., 1997, Investigative Ophthalmology and Visual Science, V38, pS560
  • [2] Dean T., 1997, Investigative Ophthalmology and Visual Science, V38, pS813
  • [3] Donohue EK, 1996, J GLAUCOMA, V5, P68
  • [4] CARBONIC-ANHYDRASE INHIBITOR SIDE-EFFECTS - SERUM CHEMICAL-ANALYSIS
    EPSTEIN, DL
    GRANT, WM
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1977, 95 (08) : 1378 - 1382
  • [5] PATIENT TOLERANCE TO CARBONIC-ANHYDRASE INHIBITORS
    LICHTER, PR
    NEWMAN, LP
    WHEELER, NC
    BEALL, OV
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1978, 85 (04) : 495 - 502
  • [6] Shin D. H., 1997, Investigative Ophthalmology and Visual Science, V38, pS559
  • [7] Stewart R., 1997, Investigative Ophthalmology and Visual Science, V38, pS559
  • [8] A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension
    Strahlman, E
    Tipping, R
    Vogel, R
    Abrantes, P
    Alm, A
    Airaksinen, PJ
    Barnebey, H
    Borgeois, A
    Cohen, JS
    CollignonBranch, J
    Cyrlin, MN
    Demailly, P
    Ehinger, B
    George, JL
    Greve, E
    Gross, RL
    Higginbotham, EJ
    Kass, MA
    Laibovitz, RA
    Lange, U
    Lewis, RA
    Maclure, G
    McMahon, CD
    Mandelkorn, RM
    Schuman, JS
    Serle, J
    Skuta, G
    Tolia, J
    Weinreb, R
    Wilensky, J
    Zimmerman, TJ
    Clineschmidt, CM
    Lippa, EA
    Reines, SA
    Strohmaier, KM
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 122 (02) : 183 - 194
  • [9] WISTRAND PJ, 1986, INVEST OPHTH VIS SCI, V27, P419